Reversal agents for direct oral anticoagulants: A focused review

Area of Science:

• Pharmacology
• Cardiovascular Medicine
• Hematology

Background:

• Vitamin K antagonist oral anticoagulants were historically the sole outpatient therapy for stroke and thromboembolism risk reduction.
• Direct oral anticoagulants (DOACs) offer advantages over vitamin K antagonists but lack readily available reversal agents.
• A critical unmet need existed for antidotes to manage life-threatening bleeding or emergent surgical situations in patients on DOACs.

Purpose of the Study:

• To review the clinical development and mechanisms of action of novel DOAC reversal agents.
• To evaluate the pharmacokinetic and study data (animal and human) for these reversal agents.
• To outline the evidence supporting the use of idarucizumab, andexanet alpha, and ciraparantag.

Main Methods:

• Focused review of clinical development and scientific literature.
• Analysis of pharmacokinetic data for idarucizumab, andexanet alpha, and ciraparantag.
• Evaluation of animal and human study data regarding efficacy and safety.

Main Results:

• Three key reversal agents (idarucizumab, andexanet alpha, ciraparantag) have been developed.
• These agents demonstrate mechanisms to neutralize the anticoagulant effects of DOACs.
• Evidence from studies supports their potential clinical utility, though safety and optimal use require further investigation.

Conclusions:

• Novel reversal agents represent a significant advancement in managing DOAC therapy.
• These antidotes enhance the safety profile and facilitate wider adoption of DOACs.
• Further research is needed to address remaining questions regarding safety and appropriate clinical application.